FDA approved PEGylated drug

To date, eleven PEGylated proteins, antibody fragments, oligonucleotides, and small molecules have been approved by FDA are on the market, including PEGylated bovine adenosine deaminase: pegademase bovine (Adagen); and PEGylated l-asparaginase: pegaspargase (Oncaspar); PEGylated products of interferon-alpha (IFN-alpha): peginterferon-2b (PegIntron) and peginterferon-2a (Pegasys); PEGylated granulocyte colony stimulating factor (GCSF): pegfilgrastim (Neulasta); PEGylated growth hormone receptor antagonist: pegvisomant (Somavert); PEGylated a 28-nucleotide aptamer against vascular endothelial growth factor (VEGF); Pegaptanib sodium (Macugen); continuous erythropoietin receptor activator Mono-mPEG-epoetin- (Mircera); PEGylated Fab fragment of the humanized anti-tumor necrosis factor (TNF)-alpha monoclonal antibody certolizumab pegol (Cimzia); PEGylated recombinant porcine uricase (urate oxidase) (Puricase); and pegylated naloxol (naloxegol) (Movantik).

FDA approved PEGylated drug

Current Drug Research on PEGylation with Small Molecule Agents, Progress in Polymer Science, 2013, 38, 421-444

Creative PEGWorks offers the most comprehensive collection of PEGylation reagents and PEG derivatives for the drug research community.